Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

10-09-2022 | Pancreatic Cancer | ASO Author Reflections

ASO Author Reflections: Pretreatment CA 19-9 Threshold of 98 U/mL is a Reasonable Cutoff for Prognostication of Clinical Stage I and II Pancreatic Cancer

Authors: Alexa D. Melucci, MD, MS, Darren R. Carpizo, MD, PhD, Mihir M. Shah, MD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

Carbohydrate antigen 19-9 (CA 19-9) is a biomarker historically used to help screen and diagnose patients with pancreatic cancer prior to symptom onset.1 Nearly 7% of patients lack the sialylated Lewis blood group antigen for detection and may be CA 19-9 nonsecretors.2 Currently, CA 19-9 is clinically used as a prognostic marker. In both resectable and unresectable pancreatic cancer, elevated pretreatment CA 19-9 is an independent poor prognostic biomarker associated with reduced overall survival.3,4 Serum CA 19-9 levels are routinely obtained in clinical practice to monitor disease progression and response to therapy. There is a paucity of data to help determine a value below a particular threshold that predicts improved survival in patients with early stage pancreatic cancer who do and do not undergo surgical resection. …
Literature
1.
Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–5.PubMed
2.
Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19–9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47(20):5501–3.PubMed
3.
Schultz NA, Christensen IJ, Werner J, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One. 2013;8(6):e67059.CrossRefPubMedPubMedCentral
4.
5.
Metadata
Title
ASO Author Reflections: Pretreatment CA 19-9 Threshold of 98 U/mL is a Reasonable Cutoff for Prognostication of Clinical Stage I and II Pancreatic Cancer
Authors
Alexa D. Melucci, MD, MS
Darren R. Carpizo, MD, PhD
Mihir M. Shah, MD
Publication date
10-09-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12541-w

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

ASO Visual Abstract

ASO Visual Abstract: Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases

ASO Visual Abstract

ASO Visual Abstract: Glissonian Approach During Robotic Mesohepatectomy for Recurrent Colorectal Liver Metastasis

ASO Author Reflections

ASO Author Reflections: Challenges in the Management of Bowel Obstruction after Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy

Thoracic Oncology

Does Pretreatment Platelet Distribution Width Predict Prognosis in Esophageal Cancer?

ASO Visual Abstract

ASO Visual Abstract: Neoadjuvant Chemotherapy for Breast Cancer in the Elderly—Are We Accomplishing Our Treatment Goals?

ASO Visual Abstract

ASO Visual Abstract: Prognostic Impact of the Loss of Skeletal Muscle Mass during Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer